26 results on '"Low, Eric"'
Search Results
2. WEIGHT GAIN FOLLOWING PERORAL ENDOSCOPIC MYOTOMY (POEM) FOR ACHALASIA IS ASSOCIATED WITH POST-POEM GASTROESOPHAGEAL REFLUX DISEASE.
3. Evolution and evidence-based adaptations in techniques for peroral endoscopic myotomy for achalasia.
4. Epidemiology of cardiomyopathies and incident heart failure in a population-based cohort study
5. Development and Validation of the Veterans Affairs Eosinophilic Esophagitis Cohort.
6. COMPARING DIAGNOSTIC METHODS TO MEASURE SPASTIC SEGMENT AND INFORM MYOTOMY LENGTH IN TYPE 3 ACHALASIA.
7. COMPARING DIAGNOSTIC METHODS TO MEASURE SPASTIC SEGMENT AND INFORM MYOTOMY LENGTH IN TYPE 3 ACHALASIA.
8. Estimated Burden of Screening for Barrett's Esophagus in the United States.
9. Development and Validation of a National US Achalasia Cohort: The Veterans Affairs Achalasia Cohort (VA-AC).
10. A multidisciplinary personalised paradigm for achalasia
11. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial
12. Su1078: DEVELOPMENT AND VALIDATION OF A UNITED STATES NATIONAL ACHALASIA COHORT.
13. Sa1200: RISK FOR ESOPHAGEAL CANCER AMONG INDIVIDUALS WITH ACHALASIA: A NATIONAL COHORT STUDY.
14. Improving Drilling-Operations Efficiency on an Ultranarrow-Margin High-Pressure/ High-Temperature Managed-Pressure- Drilling Well With Use of a Mud Cap.
15. The Surgical Clerkship and Medical Student Performance in a Standardized Patient Case of Acute Cholecystitis
16. Risk Factors for Early-Onset Colorectal Cancer.
17. Town and Gown: Tappan Square as a Paradigm of Oberlin's Changing Vision.
18. Diagnostic Pathways of Myeloma Patients Presenting to Hospital Care and Relationship to End Organ Damage: An Analysis from the Teamm (Tackling EArly Morbidity and Mortality in Myeloma) Trial in 977 Patients
19. A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial
20. A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial
21. Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen
22. Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen
23. STAKEHOLDER PERSPECTIVES ON VALUE-BASED PRICING.
24. UK Patient Perspectives of Bisphosphonate Treatment Highlight a Lack of Knowledge On Therapeutic Benefits and Strong Preferences for Choice and Location of Treatment
25. UK Patient Perspectives of Bisphosphonate Treatment Highlight a Lack of Knowledge On Therapeutic Benefits and Strong Preferences for Choice and Location of Treatment
26. NICE: friend and foe
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.